A new OHSU study by Vivek Unni, M.D., Ph.D., and colleagues suggests a link between a rare genetic mutation and protection against Parkinson’s disease and Lewy Body dementia.
Photo Credit: OHSU/Christine Torres Hicks
Scientific Frontline: Extended "At a Glance" Summary: APOE Christchurch Mutation in Parkinson's Disease
The Core Concept: The APOE Christchurch mutation is a rare genetic variant that protects against the development of Parkinson's disease and Lewy body dementia by preventing the toxic accumulation of disease-driving proteins in the brain.
Key Distinction/Mechanism: While earlier studies established that the Christchurch mutation prevents Alzheimer's-related tau protein aggregation, new findings reveal it also blocks the accumulation of alpha-synuclein, the primary protein driving Parkinson's disease progression. It functions as a highly protective variant, described by researchers as a "super-APOE-2" mutation.
Origin/History: The protective effects of the Christchurch mutation were first identified in 2019 in a Colombian woman who was genetically predisposed to Alzheimer's disease but remained symptom-free. In November 2026, Oregon Health & Science University (OHSU) researchers Vivek Unni and Carlos Soto-Faguas published findings in Cell Reports linking the mutation's protective mechanisms to Parkinson's disease.
Major Frameworks/Components:
- Tau Protein Aggregation: The mutation actively prevents the accumulation of tau proteins, a primary hallmark of Alzheimer's disease.
- Alpha-Synuclein Accumulation: The mutation blocks the buildup of alpha-synuclein proteins, which typify the progression of Parkinson's disease and Lewy body dementia.
- APOE Gene Variants: The research builds upon existing knowledge of APOE-2, a more common protective gene variant, by demonstrating that the Christchurch mutation offers superior neuroprotection in mouse models.
Branches of Science: Molecular Genetics, Neuropharmacology, Molecular Neuroscience, Neurogenetics, Translational Medicine.
Future Application: These findings lay the groundwork for developing targeted gene therapies that introduce the APOE Christchurch mutation to forestall cognitive and motor impairments in patients with Parkinson's disease, Lewy body dementia, and Alzheimer's disease.
Why It Matters: By identifying a single genetic mutation capable of blocking the biological drivers of multiple severe neurodegenerative diseases, this research offers a unified therapeutic approach that could fundamentally alter the clinical progression of Parkinson's and Alzheimer's diseases.
A rare genetic mutation may protect against developing Parkinson’s disease and Lewy body dementia, a new study from researchers at Oregon Health & Science University suggests.
The study, published this week in the journal Cell Reports, establishes the first link between Parkinson’s disease and the APOE Christchurch mutation. The study raises the possibility of gene therapy approaches to forestall cognitive and motor impairments in Parkinson’s and related conditions.
Previous research—highlighted by a 2019 case study of a Colombian woman carrying the rare mutation—found that the mutation seems to forestall symptoms of dementia in people who are otherwise genetically destined to develop Alzheimer’s disease.
OHSU researchers working with a rodent model have now discovered a link to Parkinson’s.
“It opens up this idea that this Christchurch mutation could be helpful for a lot of things we didn’t realize before,” said senior author Vivek Unni, MD, PhD, associate professor of neurology in the OHSU School of Medicine.
Other studies in animal models have shown the Christchurch mutation prevents the aggregation of the Alzheimer’s-related tau protein in the brain.
The OHSU study published this week confirms the same process in tau, while also going a step further and showing that the Christchurch mutation also prevents the accumulation of a different type of protein, known as alpha-synuclein, that typifies the progression of Parkinson’s and Lewy body dementia.
OHSU scientists used mouse models predisposed to accumulate alpha-synuclein and tau proteins in the brain. Then, they added the Christchurch mutation to the APOE gene to observe the effects.
In each case, mice with the Christchurch mutation did not accumulate tau or alpha-synuclein proteins in the brain, despite their predisposition. In effect, the mutation seemed to protect the brain from the accumulation of proteins believed to drive both Alzheimer’s and Parkinson’s diseases.
Gene therapies are already being developed to leverage another, more common version of the APOE gene (APOE2) that also seems to be protective against Alzheimer’s.
Unni said the Christchurch mutation seems to be even more protective than APOE2 and “acts like a super-APOE-2,” at least in the mouse model examined in the new study. His lab is seeking grant funding to extend preclinical research, with the goal of advancing toward human gene therapy clinical trials.
“It would take several years to test the idea,” he said.
The research began when Unni and lead author Carlos Soto-Faguas, PhD, a postdoctoral researcher in Unni’s lab, received awards from OHSU’s Oregon Alzheimer’s Disease Research Center and Parkinson Center, and from the nonprofit organizations the American Parkinson Disease Association and Stop Alzheimer’s Now.
Funding: The research was supported by funding from Stop Alzheimer’s Now; the American Parkinson Disease Association postdoctoral research fellowship, award 1308711; a pilot grant with the OHSU Parkinson’s Center, award 10255055; and the National Institute on Aging of the National Institutes of Health under award P30AG066518.
Disclaimer: All research involving animal subjects at OHSU must be reviewed and approved by the university’s Institutional Animal Care and Use Committee (IACUC). The IACUC’s priority is to ensure the health and safety of animal research subjects. The IACUC also reviews procedures to ensure the health and safety of the people who work with the animals. No live animal work may be conducted at OHSU without IACUC approval.
Published in journal: Cell Reports
Title: Mouse APOE Christchurch protects against Aβ-induced tau and α-synuclein aggregation
Authors: Carlos M. Soto-Faguás, Abigail O’Niel, Elizabeth Saltonstall, Paul A. Mueller, Paula Sanchez-Molina, Lev M. Fedorov, Randall L. Woltjer, Jacob Raber, and Vivek K. Unni
Source/Credit: Oregon Health & Science University | Erik Robinson
Edited by: Scientific Frontline
Reference Number: gen111226_01